Applied Therapeutics unveils Phase 1/2 trial of Galactosemia treatment
Category: #health  | By Mateen Dalal  | Date: 2019-06-26 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Applied Therapeutics unveils Phase 1/2 trial of Galactosemia treatment

Galactosemia patients are in urgent need of treatment options and the company is committed to advancing AT-007 through clinical development

Reports confirm that Applied Therapeutics Inc. has recently unveiled the initiation of a Phase 1/2 clinical trial of AT-007 in Galactosemia. The study, named ACTION-Galactosemia, will investigate pharmacokinetics and safety of AT-007, which is a central nervous system penetrant Aldose Reductase inhibitor in healthy participants.

The trial will apparently then explore safety, PK and biomarker-based effects in adult subjects with Galactosemia.

Seemingly, Applied Therapeutics is a US-based clinical-stage biopharmaceutical company engaged in developing new drugs against validated molecular targets in indications of huge unmet medical needs.

Sources close to the matter mentioned that the multicenter study will mainly register patients with Classic Galactosemia, the most familiar form of Galactosemia in the US. It will also look to recruit for a single cohort of GALK deficient patients, which is commonly observed in Europe. 

According to Chief Medical Officer of Applied Therapeutics, Riccardo Perfetti, MD, PhD, dietary constraints alone cannot prevent long term complications of disease as the body endogenously creates galactose. Galactosemia patients are in urgent need of treatment options and the company is committed to advancing AT-007 through clinical development as fast as possible owing to this urgent unmet medical requirement. 

Supposedly, Applied Therapeutics is planning to optimize recent FDA guidance that allows biomarker-based development in low prevalence, gradually progressing rare metabolic diseases, like Galactosemia. 

Aldose Reductase is allegedly responsible for creation of a toxic metabolite of galactose, termed galactitol, which has been found to be responsible for several of the long-term complications in Galactosemia.  Initially, patients will be treated with a single dose of AT-007, followed by continuous 27 days of dosing. The clinical trial endpoints will remain tolerability, safety, PK and biomarker-based analyses.

Sources commented that the clinical trial will evidently determine the capability of AT-007 to repress toxic accumulation of galactitol in patients and is looking to explore viability of measuring galactitol levels in the brain through MRI.  

 

Source Credits: https://ir.appliedtherapeutics.com/news-releases/news-release-details/applied-therapeutics-announces-initiation-phase-12-study-007

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

AWS and ATOS expand collaboration to achieve digital transformation faster

AWS and ATOS expand collaboration to achieve digital transformation faster

By Mateen Dalal

Amazon's subsidiary, Amazon Web Services, Inc. (AWS), has recently entered into a global Strategic Transformation Agreement with Atos, a leader in digital transformation, high-performance computing, and information technology infrastructure. This...

LadBible to lay off 10% of its workforce amid tough business conditions

LadBible to lay off 10% of its workforce amid tough business conditions

By Mateen Dalal

LadBible, one of the U.K.'s largest success stories in online media, is laying off 10% of its workforce as a result of a decline in its share price and a warning about difficult trading conditions. The Manchester-based corporation reportedly b...

Oral-B & iADH partner to make oral care positive & accessible for all

Oral-B & iADH partner to make oral care positive & accessible for all

By Mateen Dalal

Oral-B, a well-known American oral hygiene products brand, has reportedly inked a partnership deal with iADH (International Association of Disability and Oral Health), in order to make oral care more positive, accessible, and inclusive for disabled p...